Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Camp4 Therapeutics (CAMP) EBITDA Margin (2023 - 2026)

Camp4 Therapeutics' EBITDA Margin history spans 3 years, with the latest figure at 11575.86% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 953921.0% to 11575.86% in Q4 2025 year-over-year; TTM through Dec 2025 was 2298.54%, a 564486.0% increase, with the full-year FY2025 number at 2298.54%, up 564486.0% from a year prior.
  • EBITDA Margin hit 11575.86% in Q4 2025 for Camp4 Therapeutics, down from 1899.25% in the prior quarter.
  • Over the last five years, EBITDA Margin for CAMP hit a ceiling of 840.81% in Q2 2025 and a floor of 11575.86% in Q4 2025.
  • Historically, EBITDA Margin has averaged 3523.89% across 3 years, with a median of 1967.95% in 2025.
  • The widest YoY moves for EBITDA Margin: up -953921bps in 2025, down -953921bps in 2025.
  • Tracing CAMP's EBITDA Margin over 3 years: stood at 3341.71% in 2023, then skyrocketed by 39bps to 2036.66% in 2024, then plummeted by -468bps to 11575.86% in 2025.
  • Business Quant data shows EBITDA Margin for CAMP at 11575.86% in Q4 2025, 1899.25% in Q3 2025, and 840.81% in Q2 2025.